[ Price : $8.95]
CDER and CBER launch the Rare Disease Evidence Principles process intended to bring greater speed and predictability to the review...[ Price : $8.95]
Memos posted on FDAs Web site from CBER director Vinay Prasad suggest the agency is raising the bar on future Covid-19 vaccination...[ Price : $8.95]
FDA accepts for review an Achieve Life Sciences NDA for cytisinicline, an investigational treatment for helping those seeking to q...[ Price : $8.95]
Reuters reports that drug manufacturers are turning to artificial intelligence to reduce animal testing and cut costs and time in ...[ Price : $8.95]
FDA warns Castle Rock, CO-based Compounders International Analytical Laboratory about CGMP violations and deviations in its work t...[ Price : $8.95]
FDA publishes the 2025 OTC drug monograph forecast showing eight items it expects to address over the next three years.[ Price : $8.95]
FDA approves two new denosumab biosimilars from Shanghai Henlius Biotech and Organon for treating osteoporosis and cancer-related ...[ Price : $8.95]
Merck says its oral PCSK9 inhibitor met all primary and secondary endpoints in the CORALreef Lipids Phase 3 trial.